Drug Trial Radar · NCT06878404
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
552
Actual
Start
Feb 21, 2025
Primary completion
May 25, 2026
Study completion Feb 4, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Conditions
- Arthritis, Psoriatic
Interventions
IcotrokinraDrug
Icotrokinra will be administered.
PlaceboDrug
Placebo will be administered.
Active reference comparatorDrug
Active reference drug will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants who Achieve an American College of Rheumatology (ACR) ACR 20 Response at Week 16Time frame: Week 16
Locations
155 sites in 16 countries. Site status is shown where the registry gives one.
Arthritis and Rheumatism Associates ARA Jonesboro
Jonesboro, Arkansas
Omega Research Consultants
DeBary, Florida
Integral Rheumatology And Immunology Specialists
Plantation, Florida
Clinical Research of West Florida
Tampa, Florida
Willow Rheumatology and Wellness PLLC
Willowbrook, Illinois
Joint and Muscle Research Institute
Charlotte, North Carolina
Altoona Center For Clinical Research
Duncansville, Pennsylvania
Arthritis and Rheumatology Research Institute
Allen, Texas
Naiara Alvarez MD Integrative Rheumatology of South TX
Harlingen, Texas
Cosultorios Reumatologógicos Pampa
Buenos Aires, Argentina
Mindout Research
Buenos Aires, Argentina
Hospital Central Militar Cirujano Mayor Dr Cosme Argerich
Buenos Aires, Argentina
Arsema
Ciudad de Buenos Aires, Argentina
Centro Medico Privado de Reumatologia Tucuman
Ciudad de San Miguel de Tucuman, Argentina
Consultora Integral de Salud SRL
Córdoba, Argentina
MR Medicina Reumatologica
San Fernando, Argentina
Instituto Medico De Alta Complejidad (IMAC)
San Isidro, Argentina
Ipswich Hospital
Ipswich, Australia
Rheumatology Research Unit
Maroochydore, Australia
BJC Health
Parramatta, Australia
Queen Elizabeth Hospital
South Woodville, Australia
Royal Darwin Hospital
Tiwi, Australia
MC Medtech Services Ltd
Haskovo, Bulgaria
Exacta Medica
Pleven, Bulgaria
Medical Center Artmed
Plovdiv, Bulgaria
Medical Center Teodora
Rousse, Bulgaria
Peking University Third Hospital
Beijing, China
Beijing Tong Ren Hospital Capital Medical University
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
Xiangya Hospital Central South University
Changsha, China
West China Hospital Sichuan University
Chengdu, China
Sichuan Provincial Peoples Hospital
Chengdu, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Nanfang Hospital of Southern Medical Hospital
Guangzhou, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
Linyi City People Hospital
Linyi, China
Jiangxi Provincial Peoples Hospital
Nanchang, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Affiliated Hospital of Nantong University
Nantong, China
Pingxiang People's Hospital
Pingxiang, China
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.